Treatment Bridging with a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma

Cancer treatment, particularly that of multiple myeloma (MM), has drastically evolved over the past decade as we better understood the tumor microenvironment and began utilizing therapies to target tumor cells1,2. This has been accomplished with monoclonal and bispecific antibodies as well as chimeric antigen receptor (CAR)-T cell therapy3-5. However, management of patients who have failed approved agents and have rapidly progressive disease with cytopenias continues to be challenging. Many patients hope to qualify for a clinical trial option, particularly when their disease becomes triple-class or penta-refractory with a subsequent survival on the order of 6 months6,7.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 10, 2021 Category: Hematology Authors: Tarek H. Mouhieddine, Julia Hieulle, Erin Moshier, Shambavi Richard, Joshua Richter, Hearn Jay Cho, Samir Parekh, Bart Barlogie, Ajai Chari, Sundar Jagannath, Deepu Madduri Source Type: research